

REMARKS

The application is subject to a restriction requirement.

The Examiner has restricted the invention under 35 U.S.C. §121 into the following groups:

- I. Claims 1 and 3, drawn to a method of enhancing or stimulating neurogenesis, classified in class 514, subclass 646+.
- II. Claims 5-7, drawn to a method of treating symptoms of Cerebral Palsy, classified in class 514, subclass 646+.
- III. Claims 10-11, drawn to a method for the treatment of the symptoms of Torticollis, classified in class 514, subclass 646+.
- V. Claims 18-19, drawn to a method for the treatment of the symptoms of Dyskinesia, classified in class 514, subclass 646+.
- VI. Claims 22-23, drawn to a method for the treatment of the symptoms of Institutionalization and Concentration Camp Syndromes, classified in class 514, subclass 646+.
- VII. Claims 26-28, drawn to a method for the treatment of the symptoms of Dementia, classified in class 514, subclass 646+.
- VIII. Claims 31-32, drawn to a method for the treatment of neurological, behavioral, and cognitive disorders, classified in class 514, subclass 646+.
- IX. Claim 33, drawn to a method for the treatment of the symptoms of Sick Building Syndrome, classified in class 514, subclass 646+.
- X. Claim 34, drawn to a method for the treatment of the symptoms of Gulf War Syndrome, classified in class 514, subclass 646+.
- XI. Claims 35-38, drawn to a method for the treatment of the symptoms of Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome, classified in class 514, subclass 646+.
- XII. Claim 39, drawn to a method for the treatment of the symptoms of Retinitis Pigmentosa, classified in class 514, subclass 646+.

XIII. Claim 40, drawn to a method for the treatment of the symptoms of organic brain impairments, classified in class 514, subclass 646+.

XIV. Claim 41, drawn to a method for the treatment of the sexual disorders, classified in class 514, subclass 646+.

Applicant acknowledges that Examiner's statements that claims 1, 5, 6, 10, 18, 22, 26, and 27 are generic to the following disclosed patentably distinct species: a compound that is a selective inhibitor for dopamine, serotonin, and norepinephrine.

Further, Applicant acknowledges that Examiner's statement that claim 18 is generic to a plurality of disclosed patentably distinct species comprising Dyskinesia, Tardive dyskinesia, Lingual dyskinesia, and Facial dyskinesia. Additionally, Applicant acknowledges the Examiner's statement that claims 26 and 27 are generic to a plurality of disclosed patentably distinct species comprising dementia, Alzheimer's dementia and non-Alzheimer's dementia.


The Examiner contends that the inventions are distinct from each other because they each are directed to treating a variety of separate and distinct diseases and symptoms of various disease states.

Applicant provisionally elects to prosecute Group XI directed toward Reflex Sympathetic Dystrophy Syndrome or Complex Regional Pain Syndrome, claims 35-38. It is believed that claims 35-38 are now in condition for allowance. Favorable action thereon is respectfully requested.

Applicant: Peter Sterling Mueller
Application No.: 10/092,144
Filed: March 6, 2002
Page 4

Should the Examiner have any questions, the Examiner is respectfully invited to contact the undersigned attorney at the telephone number set forth below.

Respectfully submitted,



Anna Lisa Gallo
Reg. No. 50,279
Attorney for Applicant

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700